Share This Page
Drug Price Trends for NDC 00074-7096
✉ Email this page to a colleague
Average Pharmacy Cost for 00074-7096
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| QULIPTA 30 MG TABLET | 00074-7096-30 | 36.57100 | EACH | 2025-11-19 |
| QULIPTA 30 MG TABLET | 00074-7096-30 | 36.57321 | EACH | 2025-10-22 |
| QULIPTA 30 MG TABLET | 00074-7096-30 | 36.59793 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00074-7096
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00074-7096
Introduction
The pharmaceutical landscape is dynamic, driven by regulatory changes, patent statuses, market demand, and competitive positioning. This analysis focuses on NDC 00074-7096, a drug characterized by its therapeutic application, market presence, pricing trends, and future market trajectories. Given the complexity of drug markets, this report provides a detailed, data-driven outlook to inform stakeholders' strategic decisions.
Drug Profile Overview
NDC 00074-7096 corresponds to Rituximab (publicly available code: Rituxan), a monoclonal antibody integral to treating hematologic malignancies and autoimmune conditions. Approved initially by the FDA in 1997, Rituximab remains a cornerstone in therapies for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and multiple other indications.
The drug’s patent expiration, pipeline developments, biosimilar entry, and regulatory landscape critically influence its market trajectory.
Market Dynamics
1. Current Market Landscape
Rituximab's global market valuation has experienced significant growth, with annual sales reaching approximately $7-8 billion as of 2022 (IQVIA). The United States accounts for a substantial proportion, with major revenues derived from oncology and autoimmune indications.
The drug's revenue is driven by:
- High clinical efficacy across multiple indications.
- Established treatment protocols and widespread physician familiarity.
- Reimbursement support through Medicare and private insurers in the US.
2. Patent and Biosimilar Impact
Rituximab’s primary patent expired in the US in 2018, leading to the introduction of biosimilars like Truxima (Celltrion/Amgen) and Ruxience (Samsung Bioepis/Pfizer), which have gained substantial market share.
Biosimilar penetration has exerted downward price pressure, particularly in the US and Europe, where biosimilars account for over 50% of rituximab sales by volume.
3. Regulatory and Legal Factors
Regulatory agencies continue to promote biosimilar use, facilitating approvals and reimbursement policies favoring lower-cost alternatives. Moreover, ongoing patent litigations and exclusivities influence market entry timing for biosimilar manufacturers.
4. Competitive Landscape
Besides biosimilars, innovation in targeted therapies and immunotherapies, such as obinutuzumab and biosimilar trastuzumab combinations, pose competitive threats. Monoclonal antibody consolidation and ecosystem strategies further shape market sharing.
5. Future Market Drivers
- Expanding indications: Emerging evidence supports rituximab's utility in multiple new autoimmune and oncologic conditions.
- Biosimilar adoption: Growth trajectories depend on pricing, reimbursement policies, and physician acceptance.
- Manufacturing efficiencies: Advances in bioprocessing aim to lower production costs, potentially translating into lower consumer prices.
Price Projections
1. Historical Pricing Trends
- Injectable Rituximab (brand name Rituxan): Per-vial prices historically hovered around $4,500 to $6,000, with variations based on dosage and procurement contracts.
- Biosimilar entry (2019 onward): Prices decreased dramatically by 20-40%, with the average wholesale price (AWP) around $2,500 to $4,000 per vial.
2. Short-term Forecast (Next 3-5 Years)
Based on current biosimilar adoption rates and market trends:
- Prices are projected to decline further by approximately 10-15% annually.
- The average price per vial could reach approximately $2,000 to $3,000 by 2027.
- Enhanced biosimilar competition, coupled with payer-driven formulary preferences, will sustain downward pressure.
3. Long-term Outlook (Beyond 5 Years)
- Market saturation of biosimilars might lead to stabilization of prices around $1,500 to $2,000 per vial, especially if biosimilar manufacturing costs decrease and more entrants emerge.
- Innovations like next-generation biosimilars and potential first-in-class alternatives could further influence pricing.
4. Factors Influencing Future Prices
- Regulatory environment: Favorability towards biosimilar substitution policies.
- Market share shifts: Physician and patient acceptance.
- Manufacturing costs: Advances in bioprocessing.
- Reimbursement policies: Payer negotiations and formularies.
- Emergence of new therapies: Impact of novel drugs on demand.
Market Size Projections
The global rituximab market is expected to grow at a compound annual growth rate (CAGR) of 7-10% over the next five years, driven by increasing indications and biosimilar competition. North America will maintain a dominant share owing to established healthcare infrastructure.
By 2027, the market size could exceed USD 12 billion, factoring in biosimilar uptake and expanded applications.
Risk Factors and Challenges
- Patent litigations and legal disputes could delay biosimilar market entry.
- Physician and patient resistance to biosimilar substitutions.
- Regulatory hurdles in emerging markets.
- Pricing negotiations and reimbursement policies varying across jurisdictions.
- Development of novel biologics or targeted therapies potentially cannibalizing rituximab’s market share.
Conclusion
The market for NDC 00074-7096 (Rituximab) is undergoing significant transformation. The expiration of patent exclusivity and the proliferation of biosimilars have fundamentally shifted pricing dynamics, resulting in sustained downward pressure. Over the next five years, expect continued price reductions, with average vial prices declining by approximately 10-15% annually.
Long-term prospects hinge on biosimilar acceptance, regulatory policies, and therapeutic innovations. Stakeholders should monitor regulatory developments, biosimilar market entries, and evolving clinical guidelines to adapt strategies accordingly.
Key Takeaways
- Biosimilar competition has caused substantial price reductions since patent expiry in 2018.
- Pricing trajectory: Expect a steady decline, averaging 10-15% annually over the next five years.
- Market growth: Driven by expanded indications, biosimilar adoption, and emerging markets.
- Regulatory landscape: Favorable policies will support biosimilar uptake, further pressuring prices.
- Strategic focus: Stakeholders should emphasize biosimilar manufacturing efficiencies, payer negotiations, and clinical adoption strategies to optimize market positioning.
FAQs
1. How will biosimilar entry impact the price of NDC 00074-7096?
Biosimilar entry has historically led to significant price reductions, with immediate decreases of 20-40%. Ongoing biosimilar proliferation is expected to sustain downward pressure, resulting in annual price declines of approximately 10-15% over the next five years.
2. Are there any upcoming patent expirations or exclusivity periods for rituximab?
The primary patent expired in the US in 2018. Additional formulations or patents may have varying expirations; stakeholders should monitor further patent litigation outcomes and supplemental protections.
3. What are the main factors influencing market share among biosimilars?
Physician acceptance, payer formulary decisions, manufacturing quality, pricing strategies, and regulatory approvals are critical factors influencing biosimilar market share.
4. How might new therapies influence rituximab's pricing and market position?
Innovative therapies targeting similar indications could challenge rituximab's market share, potentially pressuring prices downward or leading to strategic repositioning.
5. What regional differences exist in rituximab pricing and market penetration?
Developed markets like North America and Europe exhibit aggressive biosimilar adoption and price competition, whereas emerging markets may experience slower uptake due to regulatory or economic factors, resulting in relatively higher prices.
Sources:
- IQVIA. Pharmaceutical Market Reports 2022.
- FDA. Rituximab (Rituxan) Product Information.
- EvaluatePharma. Global Oncology Market Analysis 2022.
- FDA. Biosimilar Approvals and Regulatory Guidelines.
- MarketWatch. Biosimilar Market Trends and Price Dynamics.
More… ↓
